Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

Summary

The purpose of this study is to assess the safety and immunogenicity of a single intramuscular (IM) injection of different doses of an respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine candidate, in adult participants aged 60 years and older. In addition, the study will evaluate the safety and immunogenicity of a booster vaccination administered 12 months after the primary vaccination in a subset of the study population.

Timeline

Start

2023-11-01

Primary completion

2026-02-27

Completion

2026-02-27

Drugs

Indications